{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:07:28Z","timestamp":1788959248411,"version":"build-2803163510"},"reference-count":105,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7254505"],"award-info":[{"award-number":["7254505"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2023-I2M-2-001"],"award-info":[{"award-number":["2023-I2M-2-001"]}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2021-I2M-1-030"],"award-info":[{"award-number":["2021-I2M-1-030"]}]},{"award":["2023-I2M-2-001"],"award-info":[{"award-number":["2023-I2M-2-001"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"publisher"}]},{"award":["2021-I2M-1-030"],"award-info":[{"award-number":["2021-I2M-1-030"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Antibody-radionuclide conjugates (ARCs), defined as systems in which antibodies or their derivatives are linked to therapeutic or diagnostic radionuclides via covalent or non-covalent strategies, represent a promising platform for precision tumor theranostics. Their clinical application in solid tumors, however, remains constrained by poor tumor penetration, heterogeneous antigen expression, off-tumor toxicity, and an immunosuppressive tumor microenvironment. To systematically address these barriers, multidimensional strategies are being pursued. Structurally, innovations in radionuclide selection, antibody engineering, and chelator chemistry are enhancing targeting efficacy and in vivo stability. Strategically, pretargeting approaches decouple antibody localization from radionuclide delivery to minimize off-target exposure. Systematically, matched theranostic pairs enable image-guided patient stratification and personalized dosimetry. Biologically, combining ARCs with immune checkpoint inhibitors or DNA damage response inhibitors remodels the tumor microenvironment and converts localized radiation into systemic antitumor immunity. This review critically evaluates recent advances across these domains, from component optimization, pretargeting strategies, and theranostic integration, to combination regimens, and highlights the translational barriers that must be overcome to realize the full clinical potential of ARCs in solid tumors.<\/jats:p>","DOI":"10.3390\/ijms27188022","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:26:11Z","timestamp":1788956771000},"page":"8022","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody-Radionuclide Conjugates for Solid Tumors: Multidimensional Strategies from Component Engineering to Synergistic Combination Therapy"],"prefix":"10.3390","volume":"27","author":[{"given":"Mohan","family":"Zhao","sequence":"first","affiliation":[{"name":"State Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Bejing Key Laboratory of Long-Acting Targeted Delivery Technology and Applications for Peptide and Nucleic Acid Drugs, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3987-6458","authenticated-orcid":false,"given":"Xiaojun","family":"Zhao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Bejing Key Laboratory of Long-Acting Targeted Delivery Technology and Applications for Peptide and Nucleic Acid Drugs, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixiang","family":"Gao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Bejing Key Laboratory of Long-Acting Targeted Delivery Technology and Applications for Peptide and Nucleic Acid Drugs, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongguang","family":"Shao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Bejing Key Laboratory of Long-Acting Targeted Delivery Technology and Applications for Peptide and Nucleic Acid Drugs, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Bejing Key Laboratory of Long-Acting Targeted Delivery Technology and Applications for Peptide and Nucleic Acid Drugs, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuli","family":"Zhao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Bejing Key Laboratory of Long-Acting Targeted Delivery Technology and Applications for Peptide and Nucleic Acid Drugs, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41571-025-01059-1","article-title":"Understanding and overcoming multidrug resistance in cancer","volume":"22","author":"Ge","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/EJE-20-0080","article-title":"Anaplastic thyroid carcinoma: A nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades","volume":"183","author":"Engelsman","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.2967\/jnumed.125.271028","article-title":"Radiopharmaceutical Therapy: Rapid Growth, Rising Challenges, and the Critical Need for Expertise","volume":"66","author":"Jacene","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Safdar, I., Mahmood, S., Abdulwahab, M.K., Mohd Noor, S., Ge, Y., and Mohamed Sofian, Z. (2025). Inhalable Nanomaterial Discoveries for Lung Cancer Therapy: A Review. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17080996"},{"key":"ref_5","first-page":"830","article-title":"Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer","volume":"392","author":"Conforti","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"108915","DOI":"10.1016\/j.bioorg.2025.108915","article-title":"Theranostic antibody conjugates: A review of recent trends and applications in cancer","volume":"164","author":"Kheyrolahzadeh","year":"2025","journal-title":"Bioorganic Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: Current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Juzeniene, A., Stenberg, V.Y., Bruland, \u00d8.S., Revheim, M.E., and Larsen, R.H. (2022). Dual targeting with (224)Ra\/(212)Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1051825"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2967\/jnumed.111.101006","article-title":"Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies","volume":"53","author":"Erba","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bogdanovic, B., Hugonnet, F., and Montemagno, C. (2025). Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy. Cancers, 17.","DOI":"10.3390\/cancers17071247"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2967\/jnumed.109.067298","article-title":"Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy","volume":"51","author":"Amro","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1039\/D0CS00384K","article-title":"Radiolabelling of nanomaterials for medical imaging and therapy","volume":"50","author":"Pellico","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: Clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3724\/abbs.2024206","article-title":"Astatine-211 and actinium-225: Two promising nuclides in targeted alpha therapy","volume":"57","author":"Zuo","year":"2025","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","article-title":"213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: A first-in-human experience","volume":"41","author":"Kratochwil","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","first-page":"241342","article-title":"Actinium (Ac-225) Rosopatamab tetraxetan (Ac-RT) therapy in metastatic castration resistant prostate cancer (mCRPC); Radiation dosimetry, hematological toxicity, and dose-limiting toxicity (DLT)","volume":"65","author":"Vallabhajosula","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted \u03b1-Emitter Therapy with (212)Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial","volume":"63","author":"Delpassand","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.120.251983","article-title":"Comparison of CD38-Targeted \u03b1- Versus \u03b2-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model","volume":"62","author":"Minnix","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2967\/jnumed.123.266313","article-title":"Immuno-PET and Targeted \u03b1-Therapy Using Anti-Glypican-1 Antibody Labeled with (89)Zr or (211)At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma","volume":"64","author":"Watabe","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1007\/s00259-025-07238-7","article-title":"Preclinical evaluation of [(211)At]At-AuNP-ABDMPL16 for targeted alpha therapy in Melanoma","volume":"52","author":"Zhang","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00259-025-07103-7","article-title":"Radiotheranostic landscape: A review of clinical and preclinical development","volume":"52","author":"Tran","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.ijrobp.2025.03.004","article-title":"Modeling the Effect of Daughter Migration on Dosimetry Estimates for [(225)Ac]Ac-DOTATATE","volume":"122","author":"Tronchin","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tips.2026.01.001","article-title":"Targeted alpha therapy (r)evolution: Emerging nuclides for clinical applications","volume":"47","author":"Pedersen","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00259-021-05583-x","article-title":"Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: Improving radiopharmaceutical therapy by looking into the black box","volume":"49","author":"Sgouros","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.2174\/0929867329666220607160559","article-title":"Antibody-based Radiopharmaceuticals as Theranostic Agents: An Overview","volume":"29","author":"Sharma","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40364-021-00332-6","article-title":"A comprehensive comparison between camelid nanobodies and single chain variable fragments","volume":"9","author":"Asaadi","year":"2021","journal-title":"Biomark. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-L\u00f3pez, P., Ribas-Aparicio, R.M., Becerra-B\u00e1ez, E.I., Fraga-P\u00e9rez, K., Flores-Mart\u00ednez, L.F., Mateos-Ch\u00e1vez, A.A., and Luria-P\u00e9rez, R. (2022). Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy. Cancers, 14.","DOI":"10.3390\/cancers14174206"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jconrel.2017.10.036","article-title":"Targeted cancer therapy through antibody fragments-decorated nanomedicines","volume":"268","author":"Alibakhshi","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12855","DOI":"10.1021\/acs.jmedchem.4c00857","article-title":"Imaging and Monitoring HER2 Expression in Tumors during HER2 Antibody-Drug Conjugate Therapy Utilizing a Radiolabeled Site-Specific Single-Domain Antibody Probe: (68)Ga-NODAGA-SNA004-GSC","volume":"67","author":"Ge","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1021\/acs.molpharmaceut.2c00279","article-title":"99mTc-CD3813: A Nanobody-Based Single Photon Emission Computed Tomography Radiotracer with Clinical Potential for Myeloma Imaging and Evaluation of CD38 Expression","volume":"19","author":"Shi","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2967\/jnumed.124.267667","article-title":"Single Chelator-Minibody Theranostic Agents for (89)Zr PET Imaging and (177)Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer","volume":"65","author":"Ho","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1039\/D4SC07743A","article-title":"Cysteine-selective [(188)Re]Re(v) radiolabelling of a Nanobody\u00ae for targeted radionuclide therapy using a \u201cchelate-then-click\u201d approach","volume":"16","author":"Melis","year":"2025","journal-title":"Chem. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/2326-6066.CIR-17-0495","article-title":"Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs","volume":"6","author":"Dougan","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.4049\/jimmunol.1501592","article-title":"Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies","volume":"196","author":"Golay","year":"2016","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_37","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2583210","DOI":"10.1080\/19420862.2025.2583210","article-title":"From discovery to the clinic: Structural insights, engineering options, clinical, and \u2019next wave\u2019 applications of camelid-derived single-domain antibodies","volume":"17","author":"Evers","year":"2025","journal-title":"mAbs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/cac2.12330","article-title":"Antibody variable region engineering for improving cancer immunotherapy","volume":"42","author":"Lou","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Shim, H. (2020). Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations. Biomolecules, 10.","DOI":"10.3390\/biom10030360"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.2023.41.4_suppl.352","article-title":"A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant\/refractory solid tumors","volume":"41","author":"Xu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1111\/febs.12393","article-title":"The epidermal growth factor receptor variant III (EGFRvIII): Where wild things are altered","volume":"280","author":"Gan","year":"2013","journal-title":"FEBS J."},{"key":"ref_44","first-page":"382","article-title":"Abstract 328: LCB84, a TROP2-targeted ADC, for treatment of solid tumors that express TROP-2 using the hu2G10 tumor-selective anti-TROP2 monoclonal antibody, a proprietary site-directed conjugation technology and plasma-stable tumor-selective linker chemistry","volume":"82","author":"Kim","year":"2022","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1021\/acs.inorgchem.0c00168","article-title":"H2CHXhox: Rigid Cyclohexane-Reinforced Nonmacrocyclic Chelating Ligand for [nat\/67\/68Ga]Ga3+","volume":"59","author":"Wang","year":"2020","journal-title":"Inorg. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2967\/jnumed.125.270508","article-title":"Radiolabeling of CHX-A\u2033-DTPA-Antibody Conjugates with [89Zr]ZrCl4","volume":"67","author":"Lyashchenko","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1021\/ic502942a","article-title":"H2CHXdedpa and H4CHXoctapa-chiral acyclic chelating ligands for (67\/68)Ga and (111)In radiopharmaceuticals","volume":"54","author":"Ramogida","year":"2015","journal-title":"Inorg. Chem."},{"key":"ref_50","first-page":"113077","article-title":"Synthesis and evaluation of HOPO-O8-Methyl-tetrazine as a bifunctional chelator for use in [89Zr]Zr4+, [161Tb]Tb3+ and [227Th]Th4+ radioimmunoconjugates","volume":"274","author":"Randhawa","year":"2025","journal-title":"J. Inorg. Biochem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1039\/C9SC04655K","article-title":"Chelation with a twist: A bifunctional chelator to enable room temperature radiolabeling and targeted PET imaging with scandium-44","volume":"11","author":"Vaughn","year":"2020","journal-title":"Chem. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00259-011-1780-6","article-title":"Matched pairs for radionuclide-based imaging and therapy","volume":"38","author":"Bockisch","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Zhou, X., Dong, L., and Shen, L. (2021). Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals. Molecules, 26.","DOI":"10.3390\/molecules26226997"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1007\/s00259-022-05750-8","article-title":"Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers","volume":"49","author":"Xu","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"20754","DOI":"10.1021\/acs.inorgchem.3c02340","article-title":"Bispidine Chelators for Radiopharmaceutical Applications with Lanthanide, Actinide, and Main Group Metal Ions","volume":"62","author":"Kopp","year":"2023","journal-title":"Inorg. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"11748","DOI":"10.1039\/D4SC02851A","article-title":"A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements","volume":"15","author":"Wood","year":"2024","journal-title":"Chem. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"120306","DOI":"10.1016\/j.ijpharm.2021.120306","article-title":"Siderophores for medical applications: Imaging, sensors, and therapeutics","volume":"597","author":"Fan","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics: A roadmap for future development","volume":"21","author":"Herrmann","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.1021\/acs.jmedchem.3c00753","article-title":"Site-specific Conjugation of 6 DOTA Chelators to a CA19-9-targeting scFv-Fc Antibody for Imaging and Therapy","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e2402361","DOI":"10.1002\/advs.202402361","article-title":"Engineered Antibodies as Cancer Radiotheranostics","volume":"11","author":"Wei","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/acs.molpharmaceut.7b01000","article-title":"Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to (111)In and (177)Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer","volume":"15","author":"Aghevlian","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s11095-016-2082-2","article-title":"Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with (177)Lu","volume":"34","author":"Cai","year":"2017","journal-title":"Pharm. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s11095-013-1044-1","article-title":"Trastuzumab labeled to high specific activity with 111In by conjugation to G4 PAMAM dendrimers derivatized with multiple DTPA chelators exhibits increased cytotoxic potency on HER2-positive breast cancer cells","volume":"30","author":"Chan","year":"2013","journal-title":"Pharm. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2967\/jnumed.123.266388","article-title":"(212)Pb-Pretargeted Theranostics for Pancreatic Cancer","volume":"65","author":"Bauer","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s41181-024-00307-6","article-title":"Modified poly-L-lysine for use as a clearing agent in pretargeted radioimmunotherapy","volume":"9","author":"Timperanza","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_66","first-page":"1105","article-title":"Designed Ankyrin Repeat Protein-Mediated Peptide Nucleic Acid-Based Pretargeting: A Proof-of-Principle Study","volume":"66","author":"Oroujeni","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2003-09-3284","article-title":"Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma","volume":"104","author":"Forero","year":"2004","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2967\/jnumed.121.262186","article-title":"Pretargeting: A Path Forward for Radioimmunotherapy","volume":"63","author":"Cheal","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2967\/jnumed.119.236000","article-title":"Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2\u2013Negative Breast Cancer","volume":"61","author":"Rousseau","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1078-0432.CCR-20-2150","article-title":"A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy","volume":"27","author":"Santich","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nucmedbio.2010.08.013","article-title":"Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging","volume":"38","author":"Orcutt","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"38534","DOI":"10.1021\/jacs.5c12201","article-title":"Pretargeted Mitochondrial Delivery of Organoarsenicals for Cancer Immunotherapy","volume":"147","author":"Wang","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00259-011-1903-0","article-title":"Pretargeted radioimmunotherapy of colorectal cancer metastases: Models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide","volume":"38","author":"Frampas","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.7150\/thno.48810","article-title":"Alpha radioimmunotherapy using (225)Ac-proteus-DOTA for solid tumors\u2014Safety at curative doses","volume":"10","author":"Cheal","year":"2020","journal-title":"Theranostics"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1158\/1535-7163.MCT-13-0933","article-title":"Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex","volume":"13","author":"Cheal","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1021\/acs.molpharmaceut.9b00062","article-title":"Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy","volume":"16","author":"Membreno","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-18-1650","article-title":"Leveraging Bioorthogonal Click Chemistry to Improve (225)Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma","volume":"25","author":"Poty","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.2967\/jnumed.120.260687","article-title":"Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy","volume":"62","author":"Jallinoja","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev-pharmtox-010818-021118","article-title":"Engineered Protein Scaffolds as Next-Generation Therapeutics","volume":"60","author":"Gebauer","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7150\/thno.12766","article-title":"Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors","volume":"6","author":"Honarvar","year":"2016","journal-title":"Theranostics"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1038\/s41598-021-82172-w","article-title":"Glypican-3 targeted delivery of (89)Zr and (90)Y as a theranostic radionuclide platform for hepatocellular carcinoma","volume":"11","author":"Labadie","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1007\/s00259-025-07139-9","article-title":"Theranostics using (89)Zr\/(177)Lu-labeled antibody targeting erythropoietin-producing hepatocellular A2 (EphA2)","volume":"52","author":"Watabe","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"124946","DOI":"10.1016\/j.ijpharm.2024.124946","article-title":"Preclinical evaluation of (89)Zr\/(177)Lu-labeled amatuximab for theranostic application in pancreatic ductal adenocarcinoma","volume":"667","author":"Lu","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1039\/D4SC06969B","article-title":"Potential theranostics of breast cancer with copper-64\/67 sarcophagine-trastuzumab","volume":"16","author":"Rudd","year":"2025","journal-title":"Chem. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1021\/acs.molpharmaceut.0c00127","article-title":"(86\/90)Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics","volume":"17","author":"Ferreira","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s41181-025-00354-7","article-title":"It\u2019s a match: Use of the radionuclide theranostic pair (133)La\/(225)Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies","volume":"10","author":"Trommer","year":"2025","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41698-022-00263-x","article-title":"Imaging immunity in patients with cancer using positron emission tomography","volume":"6","author":"Rudd","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.7150\/thno.39203","article-title":"Integrin \u03b1(v)\u03b2(3)-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Li, M., Liu, D., Lee, D., Cheng, Y., Baumhover, N.J., Marks, B.M., Sagastume, E.A., Ballas, Z.K., Johnson, F.L., and Morris, Z.S. (2021). Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13153676"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1007\/s00259-026-07878-3","article-title":"Enhanced therapeutic efficacy of sequential 177Lu\/225Ac-LNC1004 FAP-targeted radionuclide therapy combined with anti-PD-L1 blockade in pancreatic cancer","volume":"53","author":"Shi","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Frank, C., Xiao, Z., Allen, K.J.H., Jiao, R., Malo, M.E., and Dadachova, E. (2025). (225)Actinium-armed antibody targeting CCR8(+) regulatory T cells synergizes with immunotherapy to promote tumor rejection in syngeneic colorectal cancer models. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1662216"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1021\/acs.molpharmaceut.5c01759","article-title":"Enhanced Efficacy and Safety of (177)Lu-Anti-CD25 Radioimmunotherapy by Combination with Targeted Anticancer Agents","volume":"23","author":"Kim","year":"2026","journal-title":"Mol. Pharm."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.euf.2025.04.003","article-title":"STARLITE 1: Phase 1b\/2 Study of Combined (177)Lu-Girentuximab plus Cabozantinib and Nivolumab in Treatment-na\u00efve Patients with Advanced Clear-cell Renal Cell Carcinoma","volume":"11","author":"Hasanov","year":"2025","journal-title":"Eur. Urol. Focus"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1200\/JCO.2025.43.16_suppl.5070","article-title":"PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes","volume":"43","author":"Corzo","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12967-025-07572-2","article-title":"Preclinical synergistic effects when combining a radiolabelled HER2-targeting single domain antibody with PARP inhibitor Olaparib","volume":"24","author":"Dewulf","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.112.111534","article-title":"Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor","volume":"54","author":"Shi","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/RLU.0000000000005390","article-title":"177 Lu-PSMA With Olaparib Radiosensitization Potentiates Response and Toxicity in Extensive Castration-Resistant Metastatic Prostate cancer","volume":"49","author":"Kao","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"769","DOI":"10.5534\/wjmh.220200","article-title":"Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review","volume":"41","author":"Hatano","year":"2023","journal-title":"World J. Men\u2019s Health"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41419-024-06911-3","article-title":"ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1007\/s10495-025-02136-7","article-title":"DNA damage repair inhibitors boost targeted radionuclide therapy and immunotherapy of prostate cancer","volume":"30","author":"Xu","year":"2025","journal-title":"Apoptosis Int. J. Program. Cell Death"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41392-025-02271-2","article-title":"Dual ENPP1\/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer","volume":"10","author":"Valencia","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"114109","DOI":"10.1016\/j.ejmech.2022.114109","article-title":"Recent advances in DDR (DNA damage response) inhibitors for cancer therapy","volume":"230","author":"Cheng","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"eaat1719","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci. Adv."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Yang, L., Wei, W., Yuan, X., Guo, E., Peng, P., Wang, J., and Sun, W. (2025). Targeting DNA Damage Repair to Enhance Antitumor Immunity in Radiotherapy: Mechanisms and Opportunities. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26083743"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8022\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:30:27Z","timestamp":1788957027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":105,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188022"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188022","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}